Cardiovascular Drugs Market Scope
Cardiovascular drug, any agent that affects the function of the heart and blood vessels. Drugs that act on the cardiovascular system are among the most widely used in medicine. Examples of disorders in which such drugs may be useful include hypertension (high blood pressure), angina pectoris (chest pain resulting from inadequate blood flow through the coronary arteries to the heart muscle), heart failure (inadequate output of the heart muscle in relation to the needs of the rest of the body), and arrhythmias (disturbances of cardiac rhythm).
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
Key Companies Profiled | Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals, Inc. (Belgium), AstraZeneca (United Kingdom), Sanofi (France), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Gilead Sciences, Inc. (United States) and F. Hoffmann-La Roche Ltd (Switzerland) |
CAGR | % |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cardiovascular Drugs market throughout the predicted period.
Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals, Inc. (Belgium), AstraZeneca (United Kingdom), Sanofi (France), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Gilead Sciences, Inc. (United States) and F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players that are part of study coverage.
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Cardiovascular Drugs market by Type , by Application (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies and Other) and Region with country level break-up.
On the basis of geography, the market of Cardiovascular Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2021.
Influencing Trend:
Increasing Investment In RD Activities In Development Of Cardiovascular Drugs
Market Growth Drivers:
Increasing Heart Disease Population
Challenges:
High Cost Associated To Cardiovascular Drugs
Restraints:
Rise In Cases Of Side Effects Of Cardiovascular Drugs
Opportunities:
Growing Health Care Infrastructure In Develop Region and Favorable Government Incentive Treatment of Cardiovascular
Key Target Audience
Cardiovascular Drugs Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others